Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls. (Tey et al.) With this dose fractionation is used for bleeding, there is an increase in response rates from 55%(historical) to 75%for pain, there is an increase in response rates from 25% (historical) to 45% for obstruction, there is an increase in response rates from 25% (historical) to 45%

Inclusion Criteria:

• Biopsy proven adenocarcinoma of the stomach
• Treated with palliative intent
• At least one index symptom such as bleeding, obstruction or pain
• No prior abdominal radiotherapy
• Not on chemotherapy

Exclusion Criteria:

• Patients treated with radical intent
• Previous abdominal radiotherapy
• Patients on chemotherapy